3111B |
Naloxone - Free (Unconjugated), Blood |
3111SP |
Naloxone - Free (Unconjugated), Serum/Plasma |
3111U |
Naloxone - Total (Conjugated/Unconjugated), Urine |
3113U |
Naloxone - Total (Conjugated/Unconjugated) Screen, Urine |
3116B |
Naltrexone and Metabolite - Free (Unconjugated), Blood |
3116SP |
Naltrexone and Metabolite - Free (Unconjugated), Serum/Plasma |
3116U |
Naltrexone and Metabolite - Total (Conjugated/Unconjugated), Urine |
3157U |
Cotinine and Anabasine from Secondary Exposure, Urine |
3214B |
Nitrous Oxide, Blood |
3214TI |
Nitrous Oxide, Tissue |
3225SP |
Nuedexta®, Serum/Plasma |
3250SP |
Oxalate, Serum/Plasma |
3426B |
Perfluorooctanoic Acid, Blood Overview: Monitoring for exposure to Per- and Polyfluorinated alkyl substances |
3427SP |
Perfluoroalkyl Substances (PFAS), Serum/Plasma Overview: Monitoring for exposure to Per- and Polyfluorinated alkyl substances |
3428SP |
PFASure TM, Serum/Plasma Overview: Monitoring for exposure to Per- and Polyfluorinated alkyl substances |
3429SP |
PFASure TM Expanded, Serum/Plasma Overview: Monitoring for exposure to Per- and Polyfluorinated alkyl substances |